Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are widely used to treat type2 diabetes mellitus (T2DM) by inhibiting sodium and glucose reabsorption in therenal proximal convoluted tubules, resulting in natriuresis and glucosuria,promoting osmotic diuresis and lowering blood glucose [1]. Here, SLC5A2 is linked to type 2 diabetes mellitus.